tbuckley/cabot-search huggingface dataset:
A community-based approach to educating black men in underserved communities about the risks and benefits of prostate cancer screening.
Authors: Mark Wendell Kennedy, Jacques Carter, Stephen Wright, Magnolia Contreras, Karen Marie Winkfield
Journal: Journal of Clinical Oncology (2015)

99 Background: Black men have the highest incidence of prostate cancer (PCa) and are twice as likely to die of the disease than any other race/ethnic group in the United States. The recent controversy related to PCa screening may disproportionately impact black men who are already at greatest risk from the disease. This project sets out to develop culturally-competent educational and screening programs for men in high-risk populations so they can make an informed decision about PCa screening. Methods: A community-based education and screening program targeted towards black men living in an under-resourced community in Boston, MA was implemented. A mobile PCa screening van was initially employed and stationed at a local community health center (CHC) twice annually. Education about PCa screening was provided by a trained racially-concordant patient navigator (PN). Screening was available on the van by a primary care physician (PCP). In 2013, the pre-screening educational model was incorporated into the clinical practice of a single PCP practicing at the CHC. Every male patient over the age of 40 had an educational consultation about PCa screening with the PN before seeing their PCP. The patient would then discuss screening with the doctor and decide whether to proceed at that visit. Results: From 2004 to 2013, 20 van visits were conducted at the CHC. Two-hundred seven (207) men received PCa screening education; 179 (86.5%) elected to undergo screening. Of the men screened, 26 (14.5%) were referred for further testing as a result of their screening test. From January 2013 to September 2014, 121 men received PCa education; 100 men (82.6%) were screened. Ninety percent had both prostate-specific antigen testing and a digital rectal exam. Conclusions: These data suggest that formal PCa screening education prior to meeting with a physician is welcomed and may be a way to increase baseline screening in high risk populations. This provides an opportunity to develop an individualized prostate health management program based on individual risk profiles and to carefully monitor PSA fluctuations. The ultimate goal is to reduce unnecessary interventions while capturing PCa early in men at greatest risk.
Prognostic Impact of Chromosomal Abnormalities in Elderly Patients with Multiple Myeloma Treated with High-Dose Melphalan (MEL140) and Autologous Stem Cell Transplantation.
Authors: Peter Liebisch, Christian Straka, Astrid Wimmer, Christiane Wendl, Axel Hinke, Stefan Ibach, Hartmut Döhner
Journal: Blood (2007)
Clinical and Molecular Features Of Myeloid Neoplasms Carrying SRSF2 Mutation
Authors: Chiara Elena, Luca Malcovati, Elli Papaemmanuil, Anna Gallì, Matteo G Della Porta, Ilaria Ambaglio, Marta Ubezio, Matteo C Da Vià, Elisa Bono, Anna Cattaneo, Erica Travaglino, Rosangela Invernizzi, Peter J. Campbell, Mario Cazzola
Journal: Blood (2013)
Fresh Ex Vivo Expanded Natural Killer Cells Demonstrate Robust Proliferation in Vivo in High-Risk Relapsed Multiple Myeloma (MM) Patients
Authors: Susann Szmania, Tarun K. Garg, Natalia Lapteva, Joshuah D Lingo, Amy D Greenway, Katie Stone, Emily Woods, Junaid Khan, Justin Stivers, Bijay Nair, Lee Ann Baxter-Lowe, Amberly Bost, Dario Campana, Joshua Epstein, Adrian P. Gee, Malcolm K. Brenner, Saad Z Usmani, Sarah Waheed, Cliona M. Rooney, Michele Cottler-Fox, Bart Barlogie, Frits van Rhee
Journal: Blood (2012)
Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial
Authors: Henk Lokhorst, Bronno van der Holt, Sonja Zweegman, Edo Vellenga, Sandra Croockewit, Marinus H.J. Van Oers, Peter von dem Borne, Pierre W. Wijermans, M. R Schaafsma, Okke de Weerdt, Shulamiet Wittebol, Michel Delforge, Gerard M.J. Bos, Harm Sinnige, Marinus MarwijkKooy, Peter Joosten, Monique C. Minnema, Rianne Ammerlaan, Pieter Sonneveld
Journal: Blood (2013)
Next study (JCOG1109): A three-arm randomized phase III study comparing preoperative CDDP+5-FU(CF) versus docetaxel+CF versus CF-radiation followed by esophagectomy with D2-3 lymphadenectomy for locally advanced esophageal squamous cell cancer.
Authors: Ken Kato, Hiroyasu Igaki, Yoshinori Ito, Junki Mizusawa, Yasuhiro Tsubosa, Satoru Nakagawa, Hiroyuki Daiko, Shuichi Hironaka, Harushi Udagawa, Kazuhiko Hayashi, Isao Nozaki, Masahiko Yano, Yusuke Kimura, Hisayuki Matsushita, Tetsuya Abe, Hiroshi Okabe, Kenichi Nakamura, Haruhiko Fukuda, Motohiro Hirao, Yuko Kitagawa
Journal: Journal of Clinical Oncology (2013)

TPS4152 Background: Based on the results of JCOG9907, preoperative cisplatin plus 5- fluorouracil (CF) followed by esophagectomy with D2-3 lymphadenectomy has become standard care for advanced esophageal cancer in Japan, while the standard therapy in Western countries is preoperative chemoradiotherapy. A new clinical question has thus arisen of whether CF plus docetaxel (DCF) or CF plus radiotherapy (CF-RT) shows a survival benefit over preoperative CF even with intensive surgery. Methods: Eligibility criteria include histologically proven thoracic esophageal squamous cell carcinoma with stage IB/II/III (excluding T4) based on the 7th UICC-TNM, age 20 to 75, and performance status 0 to 1. No prior chemotherapy, radiotherapy, or hormonal therapy is allowed. Adequate organ function and written informed consent are required. Patients are randomized into any of the following three arms by a minimization method balancing the arms in terms of institution and tumor depth (T1–2 versus T3). Patients in arm A (CF) receive two courses of cisplatin at 80 mg/m 2 on day 1 and fluorouracil at 800 mg/m 2 on days 1–5, repeated every three weeks. Patients in arm B (DCF) receive three courses of docetaxel at 70 mg/m 2 , cisplatin at 70 mg/m 2 on day 1, and fluorouracil at 750 mg/m 2 on days 1–5, repeated every three weeks. Patients in arm C (CF-RT) receive two courses of cisplatin at 75 mg/m 2 on day 1 and fluorouracil at 1000 mg/m 2 on days 1–4, repeated every four weeks concurrently with radiotherapy at 41.4Gy/23fr. This trial is designed to demonstrate the superiority of preoperative DCF and/or CF-RT over CF in terms of overall survival. We assumed three-year survival with preoperative CF to be 63% and expected a 10% increase in three-year survival for DCF and CF-RT. The sample size was calculated as a total of 501 patients (167 patients per arm) with a study-wise one-sided alpha level of 5%, power of 70% for each pair comparison, an accrual period of 6.25 years, and a follow-up period of three years. This trial was registered as UMIN000009482 and started in December 2012. Clinical trial information: UMIN000009482.
P1.34: First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial
Authors: Santiago Ponce Aix, Keunchil Park, Eng-Huat Tan, Kenneth O’Byrne, Li Zhang, Michael Boyer, Tony Mok, Vera Hirsh, James Chih-Hsin Yang, Angela Märten, Luis Paz-Ares
Journal: Journal of Thoracic Oncology (2016)
Ex vivo study of human visceral nociceptors
Authors: Cian McGuire, George Boundouki, James R F Hockley, David Reed, Vincent Cibert-Goton, Madusha Peiris, Victor Kung, John Broad, Qasim Aziz, Christopher Chan, Shafi Ahmed, Mohamed A Thaha, Gareth J Sanger, L Ashley Blackshaw, Charles H Knowles, David C Bulmer
Journal: Gut (2016)

Objective The development of effective visceral analgesics free of deleterious gut-specific side effects is a priority. We aimed to develop a reproducible methodology to study visceral nociception in human tissue that could aid future target identification and drug evaluation. Design Electrophysiological (single unit) responses of visceral afferents to mechanical (von Frey hair (VFH) and stretch) and chemical (bradykinin and ATP) stimuli were examined. Thus, serosal afferents (putative nociceptors) were used to investigate the effect of tegaserod, and transient receptor potential channel, vanilloid 4 (TRPV 4 ) modulation on mechanical responses. Results Two distinct afferent fibre populations, serosal (n=23) and muscular (n=21), were distinguished based on their differences in sensitivity to VFH probing and tissue stretch. Serosal units displayed sensitivity to key algesic mediators, bradykinin (6/14 units tested) and ATP (4/10), consistent with a role as polymodal nociceptors, while muscular afferents are largely insensitive to bradykinin (0/11) and ATP (1/10). Serosal nociceptor mechanosensitivity was attenuated by tegaserod (−20.8±6.9%, n=6, p&lt;0.05), a treatment for IBS, or application of HC067047 (−34.9±10.0%, n=7, p&lt;0.05), a TRPV 4 antagonist, highlighting the utility of the preparation to examine the mechanistic action of existing drugs or novel analgesics. Repeated application of bradykinin or ATP produced consistent afferent responses following desensitisation to the first application, demonstrating their utility as test stimuli to evaluate analgesic activity. Conclusions Functionally distinct subpopulations of human visceral afferents can be demonstrated and could provide a platform technology to further study nociception in human tissue.
Review: In patients with depressive disorders, EPA-predominant omega-3 HUFAs improve depression symptoms
Authors: Gregory Simon
Journal: Annals of Internal Medicine (2016)

ACP Journal Club20 September 2016Review: In patients with depressive disorders, EPA-predominant omega-3 HUFAs improve depression symptomsGregory Simon, MD, MPHGregory Simon, MD, MPHGroup Health Research Institute, Seattle, Washington, USA (G.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/ACPJC-2016-165-6-029 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationHallahan B, Ryan T, Hibbeln JR, et al. Efficacy of omega-3 highly unsaturated fatty acids in the treatment of depression. Br J Psychiatry. 2016 Apr 21. [Epub ahead of print] https://pubmed.ncbi.nlm.nih.gov/27103682Clinical Impact RatingsGIM/FP/GP: Mental Health: References1 Fournier JC, DeRubeis RJ, Hollon SD, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303:47-53. [PMID: 20051569] Google Scholar2 Bower P, Kontopantelis E, Sutton A, et al. Influence of initial severity of depression on effectiveness of low intensity interventions: meta-analysis of individual patient data. BMJ. 2013;346:f540. [PMID: 23444423] Google Scholar Author, Article, and Disclosure InformationAffiliations: Group Health Research Institute, Seattle, Washington, USA (G.S.)This article was published at Annals.org on 6 September 2016. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoReview: Omega-3 HUFAs added to antidepressant therapy may reduce depression symptoms Gregory Simon Review: Omega-3 HUFAs added to antidepressant therapy may reduce depression symptoms Gregory Simon Metrics 20 September 2016Volume 165, Issue 6Page: JC29KeywordsAlcoholismAntidepressantsBipolar disorderDepressionFatty acidsFolic acidMajor depressive disorderPatientsPsychiatry and mental healthStatistical data ePublished: 20 September 2016 Issue Published: 20 September 2016 Copyright & PermissionsCopyright © 2016 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Hypoxia-Inducible Factor-2A Affects Fibrogenic Progression of Experimental Non-Alcoholic Fatty Liver Disease
Authors: S. Sutti, E. Morello, S. Cannito, E. Novo, C. Bocca, B. Foglia, S. Bruzzì, G. Villano, P. Pontisso, E. Bugianesi, E. Albano, M. Parola
Journal: Journal of Hepatology (2016)
Effects of Eculizumab Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Receiving Concurrent Immunosuppressive Therapy for Bone Marrow Insufficiency.
Authors: Hubert Schrezenmeier, Joerg Schubert, Lucio Luzzatto, Petra Muus, Gerard Socie, Antonio M. Risitano, Anita Hill, Peter Hillmen
Journal: Blood (2009)
Leptospirose au Portugal : situation épidémiologique de 1991 à 1997
Authors: J M Falcão, P J Nogueira, C MatiasDias, Z. P. Pimenta
Journal: Eurosurveillance (1999)

Le terme leptospirose s’applique a une serie d’affections causees par un membre de l’ordre des Spirochaetales, essentiellement l’espece Leptospira interrogans. L’infection peut etre asymptomatique, mais une maladie de gravite variable et aux tableaux cliniques varies (suggerant souvent une meningite, une encephalite ou une grippe) peut se developper. La duree de la leptospirose varie de quelques jours a plusieurs semaines, selon la gravite et le traitement. Le taux de mortalite est faible, mais peut depasser les 20% chez des sujets qui developpent une insuffisance hepatique ou renale (maladie de Weil) ou chez les personnes âgees.
International Consortium for the Study of Clinical and Molecular Aspects of Bernard-Soulier Syndrome
Authors: Anna Savoia, Shinji Kunishima, Patrizia Noris, Nuria Pujol-Moix, Dermot Kenny, Nurit Rosenberg, Margaret L. Rand, Barbara Zieger, Ali F. Gargouri, Miriam P Beltrame, Felisa C. Molinas, Mehran Karimi, Christopher Ward, Philip Kuriakose, Nadia Ewing, Carol Diamond, Alok Srivastava, Carlo Luigi Balduini, Francois Lanza
Journal: Blood (2011)
Efficacy of BLU-285, a novel, potent inhibitor of Exon 17 Mutant KIT and PDGFRA D842V, in patient-derived xenograft model of gastrointestinal stromal tumor (GIST).
Authors: Yemarshet Kelemework Gebreyohannes, Madelina-Elena Zhai, Agnieszka Wozniak, Jasmien Wellens, Jasmien Cornillie, Erica Evans, Alexandra K. Gardino, Nancy E. Kohl, Maria Debiec-Rychter, Raf Sciot, Patrick Schöffski
Journal: Journal of Clinical Oncology (2016)

11030 Background: In the majority of GISTs, oncogenic signaling is driven by mutated KIT. Patients are treated with tyrosine kinase inhibitors (TKIs) such as imatinib, sunitinib or regorafenib. Resistance to TKIs is mainly caused by secondary KIT mutations in exons 13 and 17. BLU-285 was developed at Blueprint Medicines as a potent and selective inhibitor of exon 17 mutant KIT. We investigated the efficacy of BLU-285 in a TKI-resistant KIT exon 11/17 mutant GIST PDX model. Methods: NMRI nu/nu mice were bilaterally transplanted with the human GIST xenograft, UZLX-GIST9, which carries KIT:p.P577del;W557LfsX5;D820G mutations. Mice were divided into 5 groups: control (vehicle), imatinib (50 mg/kg/bid), regorafenib (30 mg/kg/qd) and two doses of BLU-285 (10 and 30 mg/kg/qd). Animals were dosed orally for 16 days. Efficacy was assessed by tumor volume measurement, histopathology, immunohistochemistry [Ki67, pHistone H3, cleaved PARP, pMAPK] and immunoblot analysis of KIT signaling. Histologic response (HR) was graded as previously described*. Mann Whitney U test was used for statistical analysis, and a p value of < 0.05 was considered significant. Results: BLU-285 was well tolerated at all administered doses. 30 mg/kg BLU-285 resulted in significant tumor regression (27% of baseline), ≥ grade 2 HR in 60% of tumors and complete absence of proliferation. The anti-tumor effects observed with BLU-285 were significantly better than that seen with either imatinib or regorafenib. Compared to control, BLU-285 (30 mg/kg) significantly increased apoptosis (3.4-fold; p < 0.001), comparable to regorafenib. At 10 mg/kg, BLU-285 stabilized tumor volume (83% of baseline) and had significant antiproliferative effects (27-fold decrease, p < 0.001). Both doses led to a pronounced decrease of pMAPK and KIT signaling. Conclusions: BLU-285 showed dose-dependent, robust anti-tumor efficacy in a TKI- resistant KIT exon 11/17 mutant GIST PDX model through inhibition of tumor growth, proliferation, KIT signaling and induction of apoptosis. These data support the ongoing phase I clinical trial NCT02508532. * Antonescu CR, et al. Clin Cancer Res 2005; 11:4182–90
Prevalence of Rectal Colonization by MDR Bacteria and Relationship with Bacterial Infection Development in Patients Admitted to a Liver ICU
Authors: V.E.P. Gonzalez, F. Marco, M. Arteaga, E. Reverter, A. Escorsell, J. Mensa, P. Gines, A. Soriano, J. Vila, J. Fernandez
Journal: Journal of Hepatology (2016)
The cancer-testis antigen MAGE-A3 is a target of FGFR2 and fibronectin signaling in thyroid cancer progression
Authors: Shereen Ezzat, Wei Liu, Tetsuo Kondo, Xuegong Zhu, Sylvia Asa
Journal: Cancer Research (2008)

AACR Annual Meeting-- Apr 12-16, 2008; San Diego, CA

3592 

We have previously shown that members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases and the adhesion molecule fibronectin (FN) are important in thyroid cancer cell proliferation, migration, and invasion. The IIIb isoform of FGFR2 is expressed in normal human thyroid tissue and is silenced epigenetically in thyroid cancer. FN is over-expressed in well-differentiated thyroid carcinoma, but expression is reduced or lost in invasive tumor cells and in poorly differentiated and anaplastic carcinomas. Forced expression of FGFR2-IIIb results in diminished or down-regulation of tumor cell proliferation; FN inhibits cell invasion and migration while enhancing adhesion. To identify targets that mediate the action of these cell surface proteins, we performed cDNA profiling of cells that over- or under-express FGFR2-IIIb or FN. A common target gene that emerged as a potential mediator of their action is the cancer-testis antigen/melanoma associated antigen (MAGE-A3) that is reciprocally expressed with FGFR2 or FN in thyroid cancer cell lines. MAGE-A3 is expressed in primary human thyroid carcinomas but not in normal thyroid tissue. Forced MAGE-A3 expression down-regulates p21 and enhances Rb phosphorylation to promote cell cycle entry in vitro; and tumor progression and lung metastasis in mouse xenografts. FGFR2 signaling through its dedicated ligand FGF7 results in enhanced histone 3 methylation and diminished acetylation, leading to transcriptional silencing of the 5’ MAGE-A3 promoter. These findings highlight MAGE-A3 as a novel target of FGFR2 and FN action in thyroid cancer and provide new evidence for histone modifications in the control of the balance between genes of opposing functions.
Outcome during and after anticoagulant therapy in cancer patients with incidentally found pulmonary embolism
Authors: Marisa Peris, David Jiménez, Ana Maestre, Carme Font, Alfonso J. Tafur, Lucia Mazzolai, Belén Xifre, Andris Skride, Francesco Dentali, Manuel Monreal
Journal: European Respiratory Journal (2016)

Current guidelines suggest treating cancer patients with incidental pulmonary embolism comparably to patients with symptomatic pulmonary embolism. We used the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) registry to compare the rate of major bleeding and symptomatic pulmonary embolism during the course of anticoagulation and after its discontinuation in cancer patients with incidental pulmonary embolism. As of March 2016, 715 cancer patients with incidental pulmonary embolism had been enrolled in RIETE. During the course of anticoagulant therapy (mean 235 days), the rate of major bleeding was higher than the rate of symptomatic pulmonary embolism (10.1 (95% CI 7.48–13.4) versus 3.17 (95% CI 1.80–5.19) events per 100 patient–years, respectively), and the rate of fatal bleeding was higher than the rate of fatal pulmonary embolism (2.66 (95% CI 1.44–4.52) versus 0.66 (95% CI 0.17–1.81) deaths per 100 patient-years, respectively). After discontinuing anticoagulation (mean follow-up 117 days), the rate of major bleeding was lower than the rate of symptomatic pulmonary embolism (3.00 (95% CI 1.10–6.65) versus 8.37 (95% CI 4.76–13.7) events per 100 patient-years, respectively); however, there were no differences in the rate of fatal events at one death each. The risk/benefit ratio of anticoagulant therapy in cancer patients with incidental pulmonary embolism is uncertain and must be evaluated in further studies.
Quantification of HBsAg in HBV Patients with Chronic Kidney Disease: Relationship with Viral Load and Histological Findings
Authors: A.S.N. Lima, C.S. Ferreira, I.R.D. de Castro, J.S. Bernardino, R. Alves, G.A. Silva, C.T. Emori, S.N. Uehara, I.M. Carvalho-Mello, V.P. Lanzoni, A.C.A. Feldner, I.S.S. Silva, A.E.B. Silva, M.L.G. Ferraz, R. Carvalho-Filho
Journal: Journal of Hepatology (2016)
Effectiveness and Safety of Sofosbuvir/Ledipasvir Treatment for Monoinfected Genotype 1 HCV Patients in Real-Life Clinical Practice: Results from Spanish Hepa-C Cohort
Authors: J. Crespo, I. Fenandez, J. Cabezas, A. Albillos, C. Perello, J. Garcia-Samaniego, M.A. Serra, M. Diago, J.M. Pascasio, M. Prieto, S. Llerena, Z. Mariño, C. Fernandez, M. Buti, R. Bañares, M.A. Simon, J. Turnes, B. Sacristan, F. Jorquera, C. Lopez, J.R. Salcines, J. Ampuero, J.J. Sanchez-Ruano, R. Morillas, C.A. Navascues, J. de la Vega, L. Bonet, M. Cuaresma, R. Andrade, J.A. Carrion, F.S. Royuela, O.L. Iacono, G. Sanchez-Antolin, E. Molina, J.A. Ruiz, S. Montoliu, X. Torras, J.M. Moreno, P.S. Pobre, J.R. Fernandez, M.F. Bermejo, F. Gea, M. Romero, D.E. Garcia, M.L. Manzano, J.L. Calleja
Journal: Journal of Hepatology (2016)
Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population
Authors: Christopher D. Hart, Alessia Vignoli, Leonardo Tenori, Gemma Leonora Uy, Ta Van To, Clement Adebamowo, Syed Mozammel Hossain, Laura Biganzoli, Emanuela Risi, Richard R. Love, Claudio Luchinat, Angelo Di Leo
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Detecting signals of micrometastatic disease in patients with early breast cancer (EBC) could improve risk stratification and allow better tailoring of adjuvant therapies. We previously showed that postoperative serum metabolomic profiles were predictive of relapse in a single-center cohort of estrogen receptor (ER)–negative EBC patients. Here, we investigated this further using preoperative serum samples from ER-positive, premenopausal women with EBC who were enrolled in an international phase III trial. Experimental Design: Proton nuclear magnetic resonance (NMR) spectroscopy of 590 EBC samples (319 with relapse or ≥6 years clinical follow-up) and 109 metastatic breast cancer (MBC) samples was performed. A Random Forest (RF) classification model was built using a training set of 85 EBC and all MBC samples. The model was then applied to a test set of 234 EBC samples, and a risk of recurrence score was generated on the basis of the likelihood of the sample being misclassified as metastatic. Results: In the training set, the RF model separated EBC from MBC with a discrimination accuracy of 84.9%. In the test set, the RF recurrence risk score correlated with relapse, with an AUC of 0.747 in ROC analysis. Accuracy was maximized at 71.3% (sensitivity, 70.8%; specificity, 71.4%). The model performed independently of age, tumor size, grade, HER2 status and nodal status, and also of Adjuvant! Online risk of relapse score. Conclusions: In a multicenter group of EBC patients, we developed a model based on preoperative serum metabolomic profiles that was prognostic for disease recurrence, independent of traditional clinicopathologic risk factors. Clin Cancer Res; 23(6); 1422–31. ©2017 AACR.